Retour

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Calendar Calendar of Events

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.

GlobeNewswire Inc. • 26/04/2024 à 15:05:00
Ocugen, Inc. Common Stock
Address: 11 GREAT VALLEY PARKWAY
Postal Code: 19355
City: MALVERN
State: PA
Phone Number: 484-328-4701
Website: https://www.ocugen.com
Status: Active
Company Info

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

List Date2014-12-03
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001372299
Composite figiBBG00194VJB1
Share Class figiBBG001TG1LS2
Market Cap342,246,353 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees84
Share Class Shares Outstanding257329999
Weighted Shares Outstanding257328085
Round Lot100
Updated date2024-05-05
Stats
Last 5 days
7-05
6-05
3-05
2-05
1-05
Last
1.57
1.625
1.345
1.366
1.375
Variance
-3.68%
20.37%
-1.61%
-3.46%
4.01%
Open
1.63
1.35
1.367
1.415
1.322
Highest
1.665
1.643
1.415
1.42
1.435
Lowest
1.665
1.64
1.415
1.42
1.425
History
PeriodVarhighestlowest
1 week
18.76%
1.435
1.415
1 month
-16.58%
2.094
1.235
3 month
199.05%
0.535
0.52
6 month
313.27%
0.387499
0.351
1 year
121.13%
0.75
0.345
3 year
-82.33%
10.62
0.345
5 year
-80.05%
8.62
0.17
10 year
-80.05%
8.62
0.17
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-21 2023-11-09 UNPUB
Assets 96,299,000 88,976,000 74,687,000 UNPUB
Current Assets 84,401,000 73,452,000 56,558,000 UNPUB
Current Liabilities 15,683,000 13,460,000 11,136,000 UNPUB
Equity 75,800,000 70,281,000 58,395,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 75,800,000 70,281,000 58,395,000 UNPUB
Liabilities 20,499,000 18,695,000 16,292,000 UNPUB
Liabilities And Equity 96,299,000 88,976,000 74,687,000 UNPUB
Noncurrent Assets 11,898,000 15,524,000 18,129,000 UNPUB
Noncurrent Liabilities 4,816,000 5,235,000 5,156,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-21 2023-11-09 UNPUB
Exchange Gains/Losses -1,000 -2,000 5,000 UNPUB
Net Cash Flow -9,304,000 2,319,000 -17,101,000 UNPUB
Net Cash Flow, Continuing -9,303,000 2,321,000 -17,106,000 UNPUB
Net Cash Flow From Financing Activities 5,496,000 15,404,000 -35,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 5,496,000 15,404,000 -35,000 UNPUB
Net Cash Flow From Investing Activities 3,441,000 5,723,000 -3,365,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 3,441,000 5,723,000 -3,365,000 UNPUB
Net Cash Flow From Operating Activities -18,240,000 -18,806,000 -13,706,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -18,240,000 -18,806,000 -13,706,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-21 2023-11-09 UNPUB
Comprehensive Income/Loss -16,499,000 -22,928,000 -14,157,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -16,499,000 -22,928,000 -14,157,000 UNPUB
Other Comprehensive Income/Loss -1,000 -3,000 5,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-21 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,498,000 -22,925,000 -14,162,000 UNPUB
Income/Loss From Continuing Operations Before Tax -16,498,000 -22,925,000 -14,162,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,498,000 -22,925,000 -14,162,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -16,498,000 -22,925,000 -14,162,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -16,498,000 -22,925,000 -14,162,000 UNPUB
Operating Expenses 17,751,000 23,733,000 15,424,000 UNPUB
Operating Income/Loss -17,751,000 -23,733,000 -15,424,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-06 2022-08-05 2022-11-08 2023-02-28
Assets 141,727,000 130,088,000 116,239,000 108,632,000
Current Assets 138,027,000 122,569,000 107,497,000 98,492,000
Current Liabilities 7,687,000 10,338,000 14,907,000 18,460,000
Equity 131,129,000 114,108,000 95,303,000 84,052,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 131,129,000 114,108,000 95,303,000 84,052,000
Liabilities 10,598,000 15,980,000 20,936,000 24,580,000
Liabilities And Equity 141,727,000 130,088,000 116,239,000 108,632,000
Noncurrent Assets 3,700,000 7,519,000 8,742,000 10,140,000
Noncurrent Liabilities 2,911,000 5,642,000 6,029,000 6,120,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-06 2022-08-05 2022-11-08 2023-02-28
Exchange Gains/Losses UNPUB UNPUB UNPUB 25,000
Net Cash Flow 34,813,000 -14,927,000 -13,393,000 -17,546,000
Net Cash Flow, Continuing 34,813,000 -14,927,000 -13,423,000 -17,571,000
Net Cash Flow From Financing Activities 50,102,000 236,000 962,000 59,475,000
Net Cash Flow From Financing Activities, Continuing 50,102,000 236,000 962,000 59,475,000
Net Cash Flow From Investing Activities -223,000 -1,366,000 -83,000 -16,967,000
Net Cash Flow From Investing Activities, Continuing -223,000 -1,366,000 -83,000 -16,967,000
Net Cash Flow From Operating Activities -15,066,000 -13,797,000 -14,302,000 -60,079,000
Net Cash Flow From Operating Activities, Continuing -15,066,000 -13,797,000 -14,302,000 -60,079,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-06 2022-08-05 2022-11-08 2023-02-28
Comprehensive Income/Loss -18,019,000 -19,471,000 -21,902,000 -81,325,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,019,000 -19,461,000 -21,902,000 -81,325,000
Other Comprehensive Income/Loss 0 0 -21,902,000 26,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-06 2022-08-05 2022-11-08 2023-02-28
Basic Earnings Per Share 0 0 0 0
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 0
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,019,000 -19,471,000 -21,922,000 -81,351,000
Income/Loss From Continuing Operations Before Tax -18,019,000 -19,471,000 -21,922,000 -81,351,000
Income Tax Expense/Benefit UNPUB UNPUB 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -18,019,000 -19,471,000 -21,922,000 -81,351,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -18,019,000 -19,471,000 -21,922,000 -81,351,000
Net Income/Loss Available To Common Stockholders, Basic -18,019,000 -19,471,000 -21,922,000 -81,351,000
Operating Expenses 18,034,000 19,565,000 23,119,000 84,868,000
Operating Income/Loss -18,034,000 -19,565,000 -23,119,000 -84,868,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-06 2021-11-09 2022-02-28
Assets 53,847,000 124,251,000 116,312,000 105,761,000
Current Assets 51,356,000 121,626,000 113,450,000 102,646,000
Current Liabilities 4,281,000 4,840,000 6,229,000 7,000,000
Equity 46,489,000 116,409,000 107,110,000 95,818,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 46,489,000 116,409,000 107,110,000 95,818,000
Liabilities 7,358,000 7,842,000 9,202,000 9,943,000
Liabilities And Equity 53,847,000 124,251,000 116,312,000 105,761,000
Noncurrent Assets 2,491,000 2,625,000 2,862,000 3,115,000
Noncurrent Liabilities 3,077,000 3,002,000 2,973,000 2,943,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-06 2021-11-09 2022-02-28
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 20,753,000 70,850,000 -8,293,000 70,919,000
Net Cash Flow, Continuing 20,753,000 70,850,000 -8,293,000 70,919,000
Net Cash Flow From Financing Activities 26,297,000 93,664,000 110,000 120,676,000
Net Cash Flow From Financing Activities, Continuing 26,297,000 93,664,000 110,000 120,676,000
Net Cash Flow From Investing Activities -261,000 -1,013,000 -350,000 -1,816,000
Net Cash Flow From Investing Activities, Continuing -261,000 -1,013,000 -350,000 -1,816,000
Net Cash Flow From Operating Activities -5,283,000 -21,801,000 -8,053,000 -47,941,000
Net Cash Flow From Operating Activities, Continuing -5,283,000 -21,801,000 -8,053,000 -47,941,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-06 2021-11-09 2022-02-28
Comprehensive Income/Loss -7,077,000 -25,952,000 -10,755,000 -58,365,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,077,000 -25,952,000 -10,755,000 -58,365,000
Other Comprehensive Income/Loss 0 0 -10,755,000 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-06 2021-11-09 2022-02-28
Basic Earnings Per Share 0 0 0 0
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 0
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,077,000 -25,952,000 -10,755,000 -58,365,000
Income/Loss From Continuing Operations Before Tax -7,077,000 -25,952,000 -10,807,000 -58,417,000
Income Tax Expense/Benefit UNPUB UNPUB -52,000 -52,000
Interest Expense, Operating 20,000 20,000 19,000 79,000
Net Income/Loss -7,077,000 -25,952,000 -10,755,000 -58,365,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,077,000 -25,952,000 -10,755,000 -58,365,000
Net Income/Loss Available To Common Stockholders, Basic -7,077,000 -25,952,000 -10,755,000 -58,365,000
Operating Expenses 7,057,000 25,610,000 10,789,000 58,028,000
Operating Income/Loss -7,057,000 -25,610,000 -10,789,000 -58,028,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-08 2020-08-14 2020-11-06 2021-03-19
Assets 12,313,745 23,758,883 20,539,574 27,376,352
Current Assets 11,362,485 22,892,661 19,758,723 25,877,682
Current Liabilities 3,314,998 7,041,353 4,130,787 3,613,551
Equity 7,297,105 14,623,027 14,421,645 21,550,441
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 7,297,105 14,623,027 14,421,645 21,550,441
Liabilities 5,016,640 9,135,856 6,117,929 5,825,911
Liabilities And Equity 12,313,745 23,758,883 20,539,574 27,376,352
Noncurrent Assets 951,260 866,222 780,851 1,498,670
Noncurrent Liabilities 1,701,642 2,094,503 1,987,142 2,212,360
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-08 2020-08-14 2020-11-06 2021-03-19
Exchange Gains/Losses 0 0 0 UNPUB
Net Cash Flow -4,250,780 11,775,030 4,137,708 16,595,483
Net Cash Flow, Continuing -4,250,780 11,775,030 4,137,708 16,595,483
Net Cash Flow From Financing Activities 488,296 14,843,018 6,812,585 31,611,038
Net Cash Flow From Financing Activities, Continuing 488,296 14,843,018 6,812,585 31,611,038
Net Cash Flow From Investing Activities -52,653 18,195 -21,030 -306,825
Net Cash Flow From Investing Activities, Continuing -52,653 18,195 -21,030 -306,825
Net Cash Flow From Operating Activities -4,686,423 -3,086,183 -2,653,847 -14,708,730
Net Cash Flow From Operating Activities, Continuing -4,686,423 -3,086,183 -2,653,847 -14,708,730
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-08 2020-08-14 2020-11-06 2021-03-19
Comprehensive Income/Loss -3,943,819 -3,613,975 -10,473,847 -21,821,953
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -3,943,819 -3,613,975 -10,473,847 -21,821,953
Other Comprehensive Income/Loss 0 0 -10,473,847 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-08 2020-08-14 2020-11-06 2021-03-19
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 7,600,414 0 10,473,847 21,864,573
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 4,191,529 3,408,885 10,473,847 21,864,573
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -3,943,819 -3,613,975 -10,473,847 -21,821,953
Income/Loss From Continuing Operations Before Tax -3,943,819 -3,613,975 -10,473,847 -21,821,953
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 14,749 248,143 291,909 720,963
Net Income/Loss -3,943,819 -3,613,975 -10,473,847 -21,821,953
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -3,943,819 -3,613,975 -10,473,847 -21,821,953
Net Income/Loss Available To Common Stockholders, Basic -3,943,819 -16,160,315 -10,473,847 -34,368,293
Operating Expenses 3,929,102 3,408,885 10,181,980 21,327,337
Operating Income/Loss -3,929,102 -3,366,265 -10,181,980 -21,284,717
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 12,546,340
Preferred Stock Dividends And Other Adjustments 0 12,546,340 0 12,546,340
Revenues 0 42,620 0 42,620
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-12 2020-03-27
Assets UNPUB UNPUB 23,618,877 16,807,446
Current Assets UNPUB UNPUB 22,818,644 15,766,219
Current Liabilities UNPUB UNPUB 35,412,756 4,543,959
Equity UNPUB UNPUB -13,093,262 11,018,411
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB -13,093,262 11,018,411
Liabilities UNPUB UNPUB 36,712,139 5,789,035
Liabilities And Equity UNPUB UNPUB 23,618,877 16,807,446
Noncurrent Assets UNPUB UNPUB 800,233 1,041,227
Noncurrent Liabilities UNPUB UNPUB 1,299,383 1,245,076
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-12 2020-03-27
Exchange Gains/Losses UNPUB UNPUB UNPUB 0
Net Cash Flow UNPUB UNPUB 26,566,379 5,816,455
Net Cash Flow, Continuing UNPUB UNPUB 26,566,379 5,816,455
Net Cash Flow From Financing Activities UNPUB UNPUB 25,612,868 25,066,455
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 25,612,868 25,066,455
Net Cash Flow From Investing Activities UNPUB UNPUB -2,446,130 -2,356,719
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -2,446,130 -2,356,719
Net Cash Flow From Operating Activities UNPUB UNPUB 3,399,641 -16,893,281
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB 3,399,641 -16,893,281
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-12 2020-03-27
Comprehensive Income/Loss UNPUB UNPUB -22,773,281 -20,243,081
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -22,773,281 -20,243,081
Other Comprehensive Income/Loss UNPUB UNPUB -22,773,281 -451
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-12 2020-03-27
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -22,773,281 -20,242,630
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -22,773,281 -20,242,630
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB 796,141 1,767,836
Net Income/Loss UNPUB UNPUB -22,773,281 -20,242,630
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -22,773,281 -20,242,630
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -22,773,281 -20,242,630
Operating Expenses UNPUB UNPUB 2,713,811 14,162,619
Operating Income/Loss UNPUB UNPUB -2,713,811 -14,162,619
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 0 0
Calendar
7 May 2024 (Time UTC) Actual Previous Consensus
★
16:30
United States
MAY 03
509000.000
4906000.000
-1430000.000
★
16:30
United States
MAY 03
★★
15:00
United States
MAR
6270000000.000
15020000000.000
14800000000.000
★
15:00
United States
MAR
★
13:00
United States
4.605
4.548
★★
12:00
United States
★★
11:30
United States
★
10:00
United States
MAY
41.800
43.200
44.100
★
09:00
United States
MAY
40.000
★
08:55
United States
MAY 03
6.000
5.500
★
07:55
United States
MAY 03
6 May 2024 (Time UTC) Actual Previous Consensus
★★
14:00
United States
Q1
★★
13:00
United States
★★
13:00
United States
Q1
★
12:50
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:OCGN240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:OCGN240419P00001500 OPASPS Put American 100 1.5 BATO 2024-04-19
O:OCGN240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:OCGN240419P00000500 OPASPS Put American 100 0.5 BATO 2024-04-19
O:OCGN240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:OCGN240419C00001500 OCASPS Call American 100 1.5 BATO 2024-04-19
O:OCGN240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:OCGN240419C00000500 OCASPS Call American 100 0.5 BATO 2024-04-19
O:OCGN240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:OCGN240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:OCGN240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:OCGN240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:OCGN240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:OCGN240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:OCGN240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:OCGN240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:OCGN240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:OCGN240315P00002000 OPASPS Put American 100 2 BATO 2024-03-15
O:OCGN240315P00001500 OPASPS Put American 100 1.5 BATO 2024-03-15
O:OCGN240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:OCGN240315P00000500 OPASPS Put American 100 0.5 BATO 2024-03-15
O:OCGN240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:OCGN240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:OCGN240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:OCGN240315C00002000 OCASPS Call American 100 2 BATO 2024-03-15
O:OCGN240315C00001500 OCASPS Call American 100 1.5 BATO 2024-03-15
O:OCGN240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:OCGN240315C00000500 OCASPS Call American 100 0.5 BATO 2024-03-15
O:OCGN240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:OCGN240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:OCGN240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:OCGN240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:OCGN240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:OCGN240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:OCGN240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:OCGN240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:OCGN240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:OCGN240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:OCGN240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:OCGN240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:OCGN240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:OCGN240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:OCGN240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:OCGN240119P00005500 OPASPS Put American 100 5.5 BATO 2024-01-19
O:OCGN240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:OCGN240119P00004500 OPASPS Put American 100 4.5 BATO 2024-01-19
O:OCGN240119P00004000 OPASPS Put American 100 4 BATO 2024-01-19
O:OCGN240119P00003500 OPASPS Put American 100 3.5 BATO 2024-01-19
O:OCGN240119P00003000 OPASPS Put American 100 3 BATO 2024-01-19
O:OCGN240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:OCGN240119P00002000 OPASPS Put American 100 2 BATO 2024-01-19
O:OCGN240119P00001500 OPASPS Put American 100 1.5 BATO 2024-01-19
O:OCGN240119P00001000 OPASPS Put American 100 1 BATO 2024-01-19
O:OCGN240119P00000500 OPASPS Put American 100 0.5 BATO 2024-01-19
O:OCGN240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:OCGN240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:OCGN240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:OCGN240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:OCGN240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:OCGN240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:OCGN240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:OCGN240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:OCGN240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:OCGN240119C00005500 OCASPS Call American 100 5.5 BATO 2024-01-19
O:OCGN240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:OCGN240119C00004500 OCASPS Call American 100 4.5 BATO 2024-01-19
O:OCGN240119C00004000 OCASPS Call American 100 4 BATO 2024-01-19
O:OCGN240119C00003500 OCASPS Call American 100 3.5 BATO 2024-01-19
O:OCGN240119C00003000 OCASPS Call American 100 3 BATO 2024-01-19
O:OCGN240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:OCGN240119C00002000 OCASPS Call American 100 2 BATO 2024-01-19
O:OCGN240119C00001500 OCASPS Call American 100 1.5 BATO 2024-01-19
O:OCGN240119C00001000 OCASPS Call American 100 1 BATO 2024-01-19
O:OCGN240119C00000500 OCASPS Call American 100 0.5 BATO 2024-01-19
O:OCGN231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:OCGN231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:OCGN231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:OCGN231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:OCGN231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:OCGN231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:OCGN231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:OCGN231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:OCGN231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:OCGN231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:OCGN231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:OCGN231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:OCGN231020P00002000 OPASPS Put American 100 2 BATO 2023-10-20
O:OCGN231020P00001500 OPASPS Put American 100 1.5 BATO 2023-10-20
O:OCGN231020P00001000 OPASPS Put American 100 1 BATO 2023-10-20
O:OCGN231020P00000500 OPASPS Put American 100 0.5 BATO 2023-10-20
O:OCGN231020C00002000 OCASPS Call American 100 2 BATO 2023-10-20
O:OCGN231020C00001500 OCASPS Call American 100 1.5 BATO 2023-10-20
O:OCGN231020C00001000 OCASPS Call American 100 1 BATO 2023-10-20
O:OCGN231020C00000500 OCASPS Call American 100 0.5 BATO 2023-10-20
O:OCGN230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:OCGN230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:OCGN230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:OCGN230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:OCGN230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:OCGN230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:OCGN230818P00001500 OPASPS Put American 100 1.5 BATO 2023-08-18
O:OCGN230818P00001000 OPASPS Put American 100 1 BATO 2023-08-18
O:OCGN230818P00000500 OPASPS Put American 100 0.5 BATO 2023-08-18
O:OCGN230818C00001500 OCASPS Call American 100 1.5 BATO 2023-08-18
O:OCGN230818C00001000 OCASPS Call American 100 1 BATO 2023-08-18
O:OCGN230818C00000500 OCASPS Call American 100 0.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024.
GlobeNewswire Inc. • 4d ago
Calendar Calendar of Events
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL.
GlobeNewswire Inc. • 5d ago
Calendar Calendar of Events
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024.
GlobeNewswire Inc. • 3w ago
News Clinical Study
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and provided acceptability of the U.S.-based trial for submission of a Marketing Authorization Application (MAA).
GlobeNewswire Inc. • 3w ago
Health Health
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).
GlobeNewswire Inc. • 4w ago
News Clinical Study
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
GlobeNewswire Inc. • 1mo ago
News News
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE: SIG) rose sharply during Wednesday’s session after the company raised its FY25 guidance. The company and Leonard Green & Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares. Signet increased its FY25 adjusted EPS outlook to $9.90 – $11.52 from $9.08 – $10.48 versus an estimate of $9.72. Signet Jewelers shares surged 9.2% to $103.80 on Wednesday. Here are some other big stocks recording gains in today’s session. Destiny Tech100 Inc. (NYSE: DXYZ) shares jumped 21.4% to $25.77. Ocugen, Inc. (NASDAQ: OCGN) shares gained 14.2% to $1.5750. HC Wainwright & Co. ...
Benzinga • 1mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT